The dermatology thing was really pushed forward by Matt and things have not worked out how we would all have liked. The design of the acne phase 2 stuffed up the US trials and questions can be asked about the phase 1 dermatitis trials given the phase 2 results.
IMO Matt is a get it up and running kinda guy who then passes the torch to others to make the most of commercialisation opportunities. Enter Vince, our $5 billion dollar man. From what I can gather Vince has serious credentials and must have been left less than impressed by the poor phase 2 outcomes. I get the feeling he has taken the bull by the horns, recognised that there is credible, independent research by multiple universities pointing to cannabinoids as an effective anti bacterial. There is serious need, serious $$$ and a quick , low cost path to market in this arena.
IMO if this company can prove to safely and effectively knock out nasal MRSA I would be amazed if at least 10 bags from here did occur very quickly. After that sky is the limit with human and animal skin infections.
- Forums
- ASX - By Stock
- Bot Chart
The dermatology thing was really pushed forward by Matt and...
-
-
- There are more pages in this discussion • 10,788 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
35.5¢ |
Change
0.030(9.23%) |
Mkt cap ! $624.4M |
Open | High | Low | Value | Volume |
33.0¢ | 36.0¢ | 33.0¢ | $2.158M | 6.236M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 150610 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.0¢ | 660749 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 150610 | 0.355 |
11 | 372273 | 0.350 |
9 | 283724 | 0.345 |
8 | 416911 | 0.340 |
7 | 506878 | 0.335 |
Price($) | Vol. | No. |
---|---|---|
0.360 | 660749 | 17 |
0.365 | 589950 | 6 |
0.370 | 440845 | 11 |
0.375 | 654384 | 3 |
0.380 | 174990 | 7 |
Last trade - 11.59am 12/07/2024 (20 minute delay) ? |
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
BOT (ASX) Chart |